|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZFPM2 |
Gene summary for ZFPM2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZFPM2 | Gene ID | 23414 |
| Gene name | zinc finger protein, FOG family member 2 | |
| Gene Alias | DIH3 | |
| Cytomap | 8q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q8WW38 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23414 | ZFPM2 | AEH-subject1 | Human | Endometrium | AEH | 1.01e-04 | 1.83e-01 | -0.3059 |
| 23414 | ZFPM2 | RNA-P10T2-P10T2-1 | Human | Lung | AAH | 7.31e-03 | 6.84e-01 | -0.1271 |
| 23414 | ZFPM2 | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 5.54e-03 | 7.27e-01 | -0.138 |
| 23414 | ZFPM2 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 8.87e-03 | 2.42e-01 | -0.2116 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00614589 | Endometrium | AEH | reproductive system development | 88/2100 | 427/18723 | 9.50e-09 | 6.41e-07 | 88 |
| GO:00486089 | Endometrium | AEH | reproductive structure development | 87/2100 | 424/18723 | 1.43e-08 | 9.12e-07 | 87 |
| GO:00605376 | Endometrium | AEH | muscle tissue development | 83/2100 | 403/18723 | 2.57e-08 | 1.50e-06 | 83 |
| GO:00017019 | Endometrium | AEH | in utero embryonic development | 73/2100 | 367/18723 | 7.18e-07 | 2.63e-05 | 73 |
| GO:00147065 | Endometrium | AEH | striated muscle tissue development | 75/2100 | 384/18723 | 1.06e-06 | 3.62e-05 | 75 |
| GO:00330022 | Endometrium | AEH | muscle cell proliferation | 51/2100 | 248/18723 | 1.26e-05 | 2.77e-04 | 51 |
| GO:00075174 | Endometrium | AEH | muscle organ development | 60/2100 | 327/18723 | 8.19e-05 | 1.22e-03 | 60 |
| GO:00604853 | Endometrium | AEH | mesenchyme development | 54/2100 | 291/18723 | 1.34e-04 | 1.83e-03 | 54 |
| GO:00465452 | Endometrium | AEH | development of primary female sexual characteristics | 24/2100 | 100/18723 | 2.27e-04 | 2.75e-03 | 24 |
| GO:00085852 | Endometrium | AEH | female gonad development | 23/2100 | 95/18723 | 2.65e-04 | 3.09e-03 | 23 |
| GO:00486387 | Endometrium | AEH | regulation of developmental growth | 58/2100 | 330/18723 | 3.45e-04 | 3.80e-03 | 58 |
| GO:00030072 | Endometrium | AEH | heart morphogenesis | 45/2100 | 246/18723 | 6.41e-04 | 6.23e-03 | 45 |
| GO:00466602 | Endometrium | AEH | female sex differentiation | 25/2100 | 114/18723 | 7.30e-04 | 6.99e-03 | 25 |
| GO:0048738 | Endometrium | AEH | cardiac muscle tissue development | 43/2100 | 236/18723 | 9.06e-04 | 8.30e-03 | 43 |
| GO:00486396 | Endometrium | AEH | positive regulation of developmental growth | 33/2100 | 174/18723 | 1.72e-03 | 1.38e-02 | 33 |
| GO:00605414 | Endometrium | AEH | respiratory system development | 37/2100 | 203/18723 | 1.97e-03 | 1.54e-02 | 37 |
| GO:00303246 | Endometrium | AEH | lung development | 33/2100 | 177/18723 | 2.30e-03 | 1.74e-02 | 33 |
| GO:0035265 | Endometrium | AEH | organ growth | 33/2100 | 178/18723 | 2.53e-03 | 1.87e-02 | 33 |
| GO:00459278 | Endometrium | AEH | positive regulation of growth | 44/2100 | 259/18723 | 3.28e-03 | 2.30e-02 | 44 |
| GO:00303236 | Endometrium | AEH | respiratory tube development | 33/2100 | 181/18723 | 3.33e-03 | 2.32e-02 | 33 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZFPM2 | SNV | Missense_Mutation | novel | c.853N>A | p.Glu285Lys | p.E285K | Q8WW38 | protein_coding | deleterious(0.02) | probably_damaging(0.985) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| ZFPM2 | SNV | Missense_Mutation | c.1413N>T | p.Lys471Asn | p.K471N | Q8WW38 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A2-A04R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD | |
| ZFPM2 | SNV | Missense_Mutation | c.1612G>T | p.Val538Phe | p.V538F | Q8WW38 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| ZFPM2 | SNV | Missense_Mutation | c.361N>T | p.Pro121Ser | p.P121S | Q8WW38 | protein_coding | tolerated(0.66) | possibly_damaging(0.879) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | |
| ZFPM2 | SNV | Missense_Mutation | c.2498N>C | p.Ser833Thr | p.S833T | Q8WW38 | protein_coding | deleterious(0.01) | probably_damaging(0.98) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZFPM2 | SNV | Missense_Mutation | c.1258N>A | p.Leu420Ile | p.L420I | Q8WW38 | protein_coding | tolerated(0.4) | benign(0.022) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| ZFPM2 | SNV | Missense_Mutation | c.500A>T | p.Asp167Val | p.D167V | Q8WW38 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ZFPM2 | SNV | Missense_Mutation | c.1582N>A | p.Leu528Met | p.L528M | Q8WW38 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A0A2-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| ZFPM2 | SNV | Missense_Mutation | c.2066G>C | p.Cys689Ser | p.C689S | Q8WW38 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| ZFPM2 | SNV | Missense_Mutation | c.465N>T | p.Lys155Asn | p.K155N | Q8WW38 | protein_coding | tolerated(0.21) | benign(0.307) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |